patient was treated with FOLFIRINOX (5-FU/folinic acid/irinotecan/oxaliplatin), but his disease progressed after 6 cycles ( Figure 1A ). He received gemcitabine/nab-paclitaxel as second-line treatment and experienced a partial response. However, he
Search Results
Pancreatic Cancer Progression in a Patient With Lynch Syndrome Receiving Immunotherapy: A Cautionary Tale
Yifan Wang, Adeline Cuggia, Alain Pacis, Jean-Christian Boileau, Victoria A. Marcus, Zu-Hua Gao, George Chong, William D. Foulkes, and George Zogopoulos
Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion
Megan Randall, Kelly Burgess, Lela Buckingham, and Lydia Usha
2 cycles of carboplatin and paclitaxel; however, she developed a hypersensitivity reaction to carboplatin with pruritus after the second cycle. She then underwent carboplatin desensitization and received 4 more cycles of carboplatin and liposomal
Small Cell Lung Cancer in Elderly Patients: A Review
Taofeek K. Owonikoko and Suresh Ramalingam
comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer . J Clin Oncol 2006 ; 24 : 5441 – 5447 . 85. Sandler A Gray R Perry MC . Paclitaxel-carboplatin alone or with bevacizumab
Erythropoiesis-Stimulating Agents in Oncology
John A. Glaspy
-alpha reduces red blood cell transfusions (RBC) in high-risk breast cancer patients with adjuvant dose-dense, sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) [abstract] . J Clinl Oncol 2005 ; 23 ( Suppl 1 ): Abstract
Management of Neuroendocrine Tumors of Unknown Origin
Ariel Polish, Maxwell T. Vergo, and Mark Agulnik
carcinoma, 62% of whom had an unknown primary, were given 4 courses of chemotherapy with paclitaxel, carboplatin, and etoposide. Major responses were seen in 53% of patients and the median survival was 14.5 months. 12 The authors note, however, that this
Indications for Minimally Invasive Surgery for Ovarian Cancer
Ernest S. Han and Mark Wakabayashi
– 76 . 41. Ozols RF Bundy BN Greer BE . Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study . J Clin Oncol
Efficacy of Oral Cryotherapy During Oxaliplatin Infusion in Preventing Oral Thermal Hyperalgesia: A Randomized Trial
Brittany Bauman, Rosemarie Mick, Eileen Martinez, Theresa M. Lawless, Lindsey Zinck, Paige Sinclair, Mary Fuhrer, Mark O’Hara, Charles J. Schneider, Peter O’Dwyer, John Plastaras, Ursina Teitelbaum, and Kim A. Reiss
patients with breast cancer. In another trial by Hanai et al, 7 the application of a limb-cooling device to one hand during paclitaxel infusion reduced the development of peripheral neuropathy (PN) compared with the untreated hand. In addition, several
Misdiagnosis of Li-Fraumeni Syndrome in a Patient With Clonal Hematopoiesis and a Somatic TP53 Mutation
Rachel L. Mitchell, Cory Kosche, Kelly Burgess, Shreya Wadhwa, Lela Buckingham, Ritu Ghai, Jacob Rotmensch, Oleksandra Klapko, and Lydia Usha
surgical debulking. Pathology was consistent with a high-grade serous carcinoma. Immunohistochemical staining was positive for TP53 ( Figure 2 ), WT-1, and ER. She received adjuvant chemotherapy with 6 cycles of carboplatin and paclitaxel. She remained
Rediagnosis of Lung Cancer as NUT Midline Carcinoma Based on Clues From Tumor Genomic Profiling
Alexander S. Baras, Jarushka Naidoo, Christine L. Hann, Peter B. Illei, Charles W. Reninger III, and Josh Lauring
.5 times the upper limit of normal. Given the constraints of his worsening performance status, he was treated with radiation to the mediastinum and lung mass with concurrent weekly dosing of carboplatin and paclitaxel (subsequently changed to nab-paclitaxel
Geriatric Assessment in Older Patients with Breast Cancer
Heidi Klepin, Supriya Mohile, and Arti Hurria
. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer) . Ann Oncol 2005 ; 16 : 253 – 258 . 16 Maione P Perrone F Gallo C